T1	Participants 37 76	acromegalic patients with macroadenomas
T2	Participants 273 328	newly diagnosed acromegalic patients with macroadenomas
T3	Participants 407 700	patients were randomly assigned to 4-month preoperative treatment with lanreotide (starting with 30 mg/2 weeks i.m. and increasing to 30 mg/week i.m. at week 8 if mean GH >2.5 microg/l on GH day curves; pretreatment group, Group 1) or to transsphenoidal surgery (direct surgery group, Group 2)
T4	Participants 838 897	A pool of 108 patients was randomly divided into two groups
